Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion

Amarin has been on a scorching run with its fish-oil derivative Vascepa after a major cardiovascular outcomes trial last year set a possible blockbuster trajectory for the drug. Now, the FDA has voted to give Vascepa a major label boost with the addition of CV risk reduction––and those blockbuster sales could be on the near horizon.